111
Participants
Start Date
July 27, 2020
Primary Completion Date
November 16, 2021
Study Completion Date
May 3, 2022
secukinumab 300 mg Q4W
secukinumab 300 mg administered every four weeks (Q4W) via a pre-filled syringe.
secukinumab 300 mg Q2W
secukinumab 300 mg administered every two weeks (Q2W) via a pre-filled syringe.
Placebo
Matching placebo administered via a pre-filled syringe
Novartis Investigative Site, Forest Hills
Novartis Investigative Site, Berlin
Novartis Investigative Site, Marseille
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Lübeck
Novartis Investigative Site, Charleston
Novartis Investigative Site, Snellville
Novartis Investigative Site, Toulouse
Novartis Investigative Site, Jacksonville
Novartis Investigative Site, Bordeaux
Novartis Investigative Site, Miami
Novartis Investigative Site, Marburg
Novartis Investigative Site, Birmingham
Novartis Investigative Site, Chambray-lès-Tours
Novartis Investigative Site, Nantes
Novartis Investigative Site, Bramsche
Novartis Investigative Site, Aachen
Novartis Investigative Site, Frankfurt
Novartis Investigative Site, Omaha
Novartis Investigative Site, Lyon
Novartis Investigative Site, Paris
Novartis Investigative Site, Rouen
Novartis Investigative Site, Houston
Novartis Investigative Site, Pflugerville
Novartis Investigative Site, München
Novartis Investigative Site, Las Vegas
Novartis Investigative Site, Erlangen
Novartis Investigative Site, Thousand Oaks
Novartis Investigative Site, Würzburg
Novartis Investigative Site, Portland
Novartis Investigative Site, Cromwell
Novartis Investigative Site, East Windsor
Novartis Investigative Site, New York
Novartis Investigative Site, Nice
Novartis Investigative Site, Halle
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY